In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin showed encouraging responses in patients with ovarian cancer with ...

Nini Wu, MD, MBA, discusses the future of technology in community oncology, particularly highlighting the pervasive topic of artificial intelligence.

Stuart J. Schnitt, MD, discussed how AI enhances cancer diagnoses and the need for professional oversight, ethical clarity, ...

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

During a live event, Pedro C. Barata, MD, MSc, discussed the case of a patient with advanced clear cell renal cell carcinoma who requires second-line therapy.

Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all ...

A panelist discusses how axatilimab, a humanized IgG4 monoclonal antibody targeting CSF-1 receptors on monocytes and macrophages, showed promising results in the AGAVE-201 trial for ...

When given to patients with hormone receptor-positive (HR+) advanced breast cancer who had received prior CDK4/6 inhibitor ...

Pedro C. Barata, MD, MSc, discusses options for metastatic hormone-sensitive prostate cancer in the community setting.

During a live event, Shuo Ma, MD, PhD, discussed the resistance mutation analysis of patients who had disease progression ...

Christopher Schenewerk, MD, addresses the taboo topic of how to help health care professionals struggling with addiction.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...